The first two of the month, issued to Celgene and Sanofi, addressed television advertisements the agency considered misleading. The medium was traditional; the reasoning potentially worrisome, according to pharma marketing experts. But since then, the agency has focused on digital communications—email, a webpage and two YouTube videos—and at least one of those hand-slaps raises questions about just how far the arm of the FDA can reach.